Nashville Biosciences
Spencer Andrei started their work experience in 2012 at Kent State University, where they served as a Research & Teaching Assistant and Graduate Researcher until 2017. Following this, they joined Vanderbilt University Medical Center as a Research Fellow from 2017 to 2020. In 2019, they transitioned to Nashville Biosciences, where they held various roles, including Business Development, Associate Marketing, and currently Business Development, Channel Partners & New Ventures.
Spencer Andrei has pursued various educational programs throughout their career. Spencer attended the MIT Sloan School of Management, where they completed an Executive Program in Strategy & Innovation. Additionally, Spencer received a fellowship at Vanderbilt University in Medicine. Spencer also holds a Doctor of Philosophy (PhD) degree in Cell/Cellular and Molecular Biology from Kent State University. Prior to that, they completed their Bachelor of Science (BS) in Biology at the University of Mount Union.
This person is not in any offices
Nashville Biosciences
Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, was created to harness the medical center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities housed within Vanderbilt University Medical Center, including BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications.